VT
Ventyx Biosciences, Inc.
VTYX · NASDAQ
$14.00 +0.00% (+$0.00)
Market Cap $1.00B
P/E Ratio -
Div. Yield -
ROE 48.11%
Bulios Fair Price
$8.56
38.9% downside
Current Price
$14
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VTYX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
34 /100
Fair P/B 5.25x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 57.96%
ROE 48.11%
ROA 50.41%
Debt
100 /100
Low Debt/Equity 0.05x
Current ratio 17.86x
Net debt/EBITDA 0.19x
Stability
20 /100
Unstable Beta 1.27x
EPS volatility 140.69%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VTYX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sheila K. Gujrathi
Employees
81
Headquarters
San Diego